[HTML][HTML] The role of survivin in diagnosis, prognosis and treatment of breast cancer
YG Lv, F Yu, Q Yao, JH Chen, L Wang - Journal of thoracic disease, 2010 - ncbi.nlm.nih.gov
Survivin is a cancer gene that is silenced in differentiated tissues, while overexpressed at
high levels in vast majority of tumors. It has garnered great interests in recent years. Some …
high levels in vast majority of tumors. It has garnered great interests in recent years. Some …
[HTML][HTML] HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with …
Background Neoadjuvant chemotherapy has been considered the standard care in locally
advanced breast cancer. However, about 20% of the patients do not benefit from this clinical …
advanced breast cancer. However, about 20% of the patients do not benefit from this clinical …
Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced …
X Li, M Liu, Y Zhang, J Wang, Y Zheng, J Li, B Ma… - Medical Oncology, 2011 - Springer
The purpose of this study was to evaluate the importance of biological markers to predict
pathologic complete response (pCR) to neoadjuvant docetaxel plus epirubicin combination …
pathologic complete response (pCR) to neoadjuvant docetaxel plus epirubicin combination …
Small breast epithelial mucin (SBEM) has the potential to be a marker for predicting hematogenous micrometastasis and response to neoadjuvant chemotherapy in …
ZZ Liu, XD Xie, SX Qu, ZD Zheng, YK Wang - Clinical & experimental …, 2010 - Springer
To investigate the potential role of small breast epithelial mucin (SBEM) as a marker for
detecting hematogenous micrometastasis in breast cancer and explore its clinical …
detecting hematogenous micrometastasis in breast cancer and explore its clinical …
TAC 方案在乳腺癌新辅助化疗中的临床疗效观察
李怡， 吴涛， 尹国武， 杨华光， 杨艳红 - 现代肿瘤医学, 2010 - cqvip.com
目的: 探讨TAC (多西他赛+ 阿霉索+ 环磷酰胺) 方案在乳腺癌新辅助化疗中的临床疗效. 方法: 35
例Ⅱb-Ⅲa 乳腺癌患者术前应用TAC 方案进行2—4 周期新辅助化疗, 观察其有效率 …
例Ⅱb-Ⅲa 乳腺癌患者术前应用TAC 方案进行2—4 周期新辅助化疗, 观察其有效率 …
[HTML][HTML] Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer …
R Sabatier, JY Pierga, H Curé, R Abulnaja… - Cancers, 2021 - mdpi.com
Simple Summary We recently published the results of the AVASTEM study, in which we
explored the impact of the addition of an angiogenesis inhibitor (bevacizumab) to standard …
explored the impact of the addition of an angiogenesis inhibitor (bevacizumab) to standard …
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery
P Kaufmann, CE Dauphine, MP Vargas… - The American …, 2006 - journals.sagepub.com
Neoadjuvant chemotherapy (NC) in patients with breast cancer results in high response
rates and has been used with the purpose of reducing tumor size and achieving breast …
rates and has been used with the purpose of reducing tumor size and achieving breast …
Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk‐adapted adjuvant therapy: A phase II trial
TL Lee, PY Wei, MH Yang, PMH Chang… - Cancer …, 2022 - Wiley Online Library
Background To assess the feasibility of tongue conservation treatment with induction
chemotherapy (ICT), tongue conservation surgery, and risk‐adapted postoperative adjuvant …
chemotherapy (ICT), tongue conservation surgery, and risk‐adapted postoperative adjuvant …
Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary …
T Le, G Alshaikh, L Hopkins, W Faught… - Annals of surgical …, 2006 - Springer
Background To examine the prognostic significance of postoperative morbidities in patients
with ovarian cancer treated with neoadjuvant chemotherapy and interval surgical debulking …
with ovarian cancer treated with neoadjuvant chemotherapy and interval surgical debulking …
乳腺癌新辅助治疗的临床效果评价
骆成玉， 林华， 季晓昕， 杨齐， 张键， 丁毅， 薛镭… - 北京医学, 2007 - cqvip.com
目的评价乳腺癌新辅助治疗的临床效果. 方法对132 例乳腺癌进行新辅助治疗,
其中采用新辅助内分泌者9 例. 紫杉醇联合表阿霉素治疗12 例, CEFi 方案治疗102 例 …
其中采用新辅助内分泌者9 例. 紫杉醇联合表阿霉素治疗12 例, CEFi 方案治疗102 例 …